Dual-action drug aims to boost heart and metabolic health in kazakh patients
NCT ID NCT07303556
First seen Jan 04, 2026 · Last updated Apr 29, 2026 · Updated 16 times
Summary
This study tests whether a newer type of diabetes medication (GIP/GLP-1 receptor agonist) can improve heart function and blood sugar control in 120 adults with both chronic heart failure and type 2 diabetes. Participants receive the drug and are monitored for 40 weeks with heart tests, blood work, and genetic profiling. The goal is to see if this treatment can reduce heart strain and support personalized care in the Kazakhstani population.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
PI "National Laboratory Astana", Nazarbayev University
Astana, Kazakhstan, 010000, Kazakhstan
Conditions
Explore the condition pages connected to this study.